Board of Directors

Chairman of the Board since 2017

Catharina Bäärnhielm, PhD, born 1952

Catharina has a broad experience from a variety of senior positions in the pharmaceutical industry, most recently as VP/Global Project Director, at AstraZeneca. Her experience spans all phases of drug development, from idea to launch. She has extensive knowledge of running collaborations between industry and academia. Current positions include chairman of Cereno Scientific AB (listed at Spotlight), board member of GU Ventures AB and Senior Advisor to Karolinska Institutet.

Holding in the Company: 0 shares

Independence: Catharina is independent in relation to the Company and the Company’s largest owner

Founder and Board member since 2015

Kjell Olmarker, PhD, born 1958

With over 100 publications in the area of chronic back pain Kjell is considered one of the world’s most renowned researchers within the area. He holds a professorship at Gothenburg University and works actively in the development of the STA363 project, conducting a majority of the project’s in vivo studies and supporting the board in scientific matters.

Holding in the Company: 700 000 shares

Independence: Kjell is dependent in relation to the Company and the Company’s largest owner

Board member since 2018

Jane Buus Laursen, PhD, born 1975

Jane Buus Laursen is Corporate Vice President and head of Novo Nordisk’s Late Stage & Commercial Business Development. Before that, she spent 15 years at AstraZeneca where she completed a large number of deals with biotechs, pharma and academia spanning from early stage to late stage business transactions across all of AstraZeneca’s strategic areas. Her CV includes licensing deals, M&As, commercial partnerships and divestments of late stage clinical and on-market assets, in addition to spin-out of early stage assets.

Holding in the Company: 0 shares

Independence: Jane is independent in relation to the Company and the Company’s largest owner

Board member since 2016

Patrik Sjöstrand, BSc, born 1973

Patrik is investment manager at Almi Invest, Sweden’s most active venture capitalist investing. For the last 20 years, Patrik has worked predominantly in start-ups and smaller corporations as a project manager, managing director and chief operating officer. He also has 10 years of experience as a board member.

Holding in the Company: 0 shares

Independence: Patrik is independent in relation to the Company and dependent in relation to the Company’s largest owner

Board member since 2017

Pontus Ottosson, MSc, born 1975

Pontus is a board member at Stayble Therapeutics AB and currently serves as Head of Investments at Chalmers Ventures. He previously led P.U.L.S, one of the most successful life science incubator / venture capital firms in Scandinavia, completing exits at a deal value of 1.1 billion SEK.

Holding in the Company: 0 shares

Independence: Pontus is independent in relation to the Company and dependent in relation to the Company’s largest owner